复发性流产患者甲状腺自身免疫患病率及左甲状腺素治疗效果
该回顾性队列研究纳入1064例复发性流产患者,按TSH水平分组,分析左甲状腺素治疗对妊娠持续率的影响。结果显示,在边界亚临床甲减患者中,治疗未改善妊娠持续率(P=0.392),且基于TPOAb状态的治疗也无差异。结论认为,妊娠期甲减治疗应基于TSH>4 mIU/l,基于甲状腺自身免疫或TSH>2.5 mIU/l启动治疗可能导致过度治疗。
要点
- 复发性流产患者中72.7%甲状腺功能正常,19.4%为边界亚临床甲减,5.4%为亚临床甲减。
- 边界亚临床甲减患者接受左甲状腺素治疗未提高妊娠持续率(P=0.392)。
- 妊娠期甲减治疗应基于TSH>4 mIU/l,避免基于TSH>2.5或甲状腺自身免疫的过度治疗。
核心结论
- 妊娠期甲减治疗应基于TSH>4 mIU/l启动。
- 基于甲状腺自身免疫或TSH>2.5 mIU/l启动治疗可能导致过度治疗。
研究设计与样本
- 回顾性队列研究,纳入1064例复发性流产患者。
- 根据TSH水平分为甲状腺功能正常组(TSH 0.1至≤2.5 mIU/l)、边界亚临床甲减组(TSH 2.5至≤4 mIU/l)和亚临床甲减组(TSH 4至≤10 mIU/l)。
- 比较治疗与未治疗的边界亚临床甲减患者(n=98)及未治疗甲状腺功能正常患者(n=279)的妊娠持续率(超过10周)。
主要发现
- 72.7%(721/992)为甲状腺功能正常,19.4%(192/992)为边界亚临床甲减,5.4%(54/992)为亚临床甲减。
- 401例有已知妊娠结局的患者中,21%接受左甲状腺素治疗。
- 57.7%的患者进行了TPOAb检测,甲状腺功能正常组阳性率9.25%(37/400),边界亚临床甲减组16.5%(22/133),亚临床甲减组35.3%(12/34)。
- 边界亚临床甲减患者中,治疗未改善妊娠持续率(P=0.392)。
- 边界亚临床甲减患者中,基于TPOAb状态和治疗与否的妊娠结局无差异(P=0.4214);甲状腺功能正常患者中,基于TPOAb状态的妊娠结局无差异(P=0.2668)。
关键数值与推荐
- 甲状腺功能正常:TSH 0.1至≤2.5 mIU/l。
- 边界亚临床甲减:TSH 2.5至≤4 mIU/l。
- 亚临床甲减:TSH 4至≤10 mIU/l。
- 妊娠持续率定义为超过10周。
临床怎么用
- 对于复发性流产患者,妊娠期甲减治疗应基于TSH>4 mIU/l启动。
- 不推荐仅基于甲状腺自身免疫或TSH>2.5 mIU/l启动左甲状腺素治疗,以避免过度治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does initiating levothyroxine treatment based on thyroid-stimulating hormone (TSH) >2.5 mIU/l or thyroid autoimmunity improve pregnancy continuation rates in recurrent pregnancy loss (RPL) patients? DESIGN: A retrospective cohort study of 1064 RPL patients, in which subjects were classified as either euthyroid (TSH 0.1 to ≤2.5 mIU/l), borderline-subclinical hypothyroid (borderline-SCH, TSH 2.5 to ≤4 mIU/l) or subclinical hypothyroid (SCH, TSH 4 to ≤10 mIU/l). For subjects with ≥2 pregnancy losses and a subsequent pregnancy with known outcome, a comparison was done of the pregnancy continuation rate past 10 weeks of treated and untreated borderline-SCH (n = 98) and untreated euthyroid (n = 279) subjects, and between subjects with positive (n = 18) and negative (n = 206) thyroid peroxidase (TPOAb tests) within the borderline-SCH and euthyroid groups. RESULTS: 72.7% were euthyroid (721/992), 19.4% (192/992) were borderline-SCH, and 5.4% (54/992) were subclinically hypothyroid (SCH). Of 401 women with a subsequent pregnancy of known outcome at 10 gestational weeks, 21% received treatment with levothyroxine. 57.7% of subjects had a TPOAb test, which was positive in 9.25% (37/400) in euthyroid, 16.5% (22/133) in borderline-SCH subjects and 35.3% (12/34) in SCH subjects. Treatment did not improve pregnancy continuation rates in borderline-SCH subjects (P = 0.392). There was no difference in pregnancy outcomes based on TPOAb status and treatment for borderline-SCH subjects (P = 0.4214), or based on TPOAb status for euthyroid subjects (P = 0.2668). CONCLUSIONS: Treatment of hypothyroidism in pregnancy should be initiated based on a TSH >4 mIU/l. Treatment initiation based on thyroid autoimmunity or a TSH >2.5 mIU/l may result in overtreatment.
引用
- Leduc-Robert G, Iews M, Abdelkareem AO, et al. Prevalence of thyroid autoimmunity and effect of levothyroxine treatment in a cohort of 1064 patients with recurrent pregnancy loss. Reprod Biomed Online. 2019. PMID: 32160949. doi:10.1016/j.rbmo.2019.11.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。